Vanc Pharmaceuticals Inc.

Vanc Pharmaceuticals Inc.

November 18, 2014 09:00 ET

Vanc Pharmaceuticals Receives Health Canada Approval for 22 Generic Molecules

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 18, 2014) - Vanc Pharmaceuticals Inc. ("Vanc" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF) is pleased to announce that it has received Notice of Compliance (NOC) from Health Canada for 22 generic molecules. These 22 molecules will comprise of 51 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy. The Notice of Compliance from Health Canada provides the authorization for Vanc to market and sell the generic molecules in Canada.

The current aggregate annual Canadian sales of these 22 products is estimated to be approximately $900 million.

"As Western Canada's first generic drug company we are excited to have made a significant step towards commercializing our brand in the Canadian generics market. Over the coming two quarters we plan to begin manufacturing these products and commence sales and marketing activities in Q2-2015," said Arun Nayyar, CEO of Vanc. "Our aim is to launch with additional products and we will provide further updates in the coming months."

Table 1.0 provides details on each of the molecules.

Molecule Name Presentations Brand Reference
1 VAN-Rizatriptan 5 MG and 10 MG Tab Maxalt™
2 VAN-Irbesartan 75 MG, 150 MG and 300 MG Tab Avapro™
3 VAN-Irbesartan-HCTZ 150+12.5 MG, 300+12.5 MG and 300+25 MG Tab Avalide™
4 VAN-Donepezil 5 MG and 10 MG Tab Aricept™
5 VAN-Amlodipine 5 MG and 10 MG Tab Norvasc™
6 VAN-Losartan 25 MG, 50 MG and 100 MG Tab Cozaar™
7 VAN-Losartan-HCTZ 50+12.5 MG and 100+25 MG Tab Hyzaar™
8 VAN-Levetiracetam 250 MG, 500 MG and 750 MG Tab Keppra™
9 VAN-Gabapentin 600 MG and 800 MG Tab Neurontin™
10 VAN-Omeperazole 20 MG DR Tab Losec™
11 VAN-Finasteride 5 MG Tab Proscar™
12 VAN-Alendronate 5 MG, 10 MG and 70 MG Tab Fosamax™
13 VAN-Bicalutamide 50 MG Tab Casodex™
14 VAN-Letrozole 2.5 MG Tab Femara™
15 VAN-Olanzapine 2.5 MG, 5 MG, 7.5 MG, 10 MG and 15 MG Tab Zyprexa™
16 VAN-Sertraline cap 25 MG, 50 MG and 100 MG Cap Zoloft™
17 VAN-Anastrozole 1 MG Tab Arimidex™
18 VAN-Pantoprazole 40 MG Tab Pantoloc™
19 VAN-Gabapentin 100 MG, 300 MG and 400 MG Cap Neurontin™
20 VAN-Ciprofloxacin 250 MG, 500 MG and 750 MG Tab Cipro™
21 VAN-Montelukast 4 MG and 5 MG Chew Tabs, 10 MG Tab Singulair™
22 VAN-Sildenafil 25 MG, 50 MG and 100 MG Tab Viagra™

On behalf of:

Vanc Pharmaceuticals Inc.

Jamie Lewin, Director and CFO

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information